Pliant Therapeutics, Inc. engages in the discovery, development and commercialization of therapies for fibrotic diseases. It offers a product discovery engine. The company is pursuing drug ...

Pliant Therapeutics said Sunday that an experimental pill significantly improved lung function in patients with idiopathic pulmonary fibrosis, or IPF, a deadly lung disease with few approved ...

Pliant Therapeutics (NASDAQ:PLRX) stock jumped 28% on Thursday after the company issued an update for a Phase 2b clinical ...

Pliant Therapeutics PLRX received a positive safety review of the ongoing INTGERIS-IPF phase IIa study evaluating PLN-74809 at 320 mg for the treatment of idiopathic pulmonary fibrosis (IPF) from ...

Pliant Therapeutics has discontinued a phase 2b/3 trial after recording at least a 7% higher rate of adverse events tied to idiopathic pulmonary fibrosis (IPF) in the treatment arms compared to ...

A clinical study testing a Pliant Therapeutics drug once considered a promising prospect for treating a fatal lung disorder is now on pause at the recommendation of independent outside observers.

Pliant Therapeutics (NASDAQ:PLRX) stock plunged 61% in the wake of news that it has paused enrollment in a Phase 2b study of its drug bexotegrast in patients with idiopathic pulmonary fibrosis ...

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel ...